|
CRISPR Therapeutics AG (CRSP) DCF Valoración
CH | Healthcare | Biotechnology | NASDAQ
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
CRISPR Therapeutics AG (CRSP) Bundle
¡Maximice la eficiencia y mejore la precisión con nuestra calculadora DCF (CRSP)! Utilizando datos reales de CRISPR Therapeutics AG y suposiciones personalizables, esta herramienta le permite pronosticar, analizar y evaluar (CRSP) como un inversor experto.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 289.6 | .5 | 913.1 | .4 | 371.2 | 371.4 | 371.6 | 371.9 | 372.1 | 372.3 |
| Revenue Growth, % | 0 | -99.81 | 168054.88 | -99.95 | 85038.99 | 0.05881422 | 0.05881422 | 0.05881422 | 0.05881422 | 0.05881422 |
| EBITDA | 51.5 | -345.3 | 391.5 | -649.0 | -202.7 | -144.1 | -144.2 | -144.3 | -144.3 | -144.4 |
| EBITDA, % | 17.77 | -63582.14 | 42.87 | -148850.69 | -54.61 | -38.79 | -38.79 | -38.79 | -38.79 | -38.79 |
| Depreciation | 4.7 | 9.2 | 18.0 | 24.2 | 19.8 | 155.2 | 155.3 | 155.4 | 155.5 | 155.6 |
| Depreciation, % | 1.63 | 1691.34 | 1.97 | 5544.04 | 5.34 | 41.79 | 41.79 | 41.79 | 41.79 | 41.79 |
| EBIT | 46.7 | -354.4 | 373.5 | -673.2 | -222.5 | -150.7 | -150.8 | -150.9 | -151.0 | -151.1 |
| EBIT, % | 16.14 | -65273.48 | 40.91 | -154394.72 | -59.95 | -40.58 | -40.58 | -40.58 | -40.58 | -40.58 |
| Total Cash | 943.8 | 1,690.3 | 2,379.1 | 1,815.3 | 1,693.7 | 371.4 | 371.6 | 371.9 | 372.1 | 372.3 |
| Total Cash, percent | .0 | .3 | .0 | .4 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .1 | .1 | .3 | .0 | 200.0 | 59.8 | 59.8 | 59.8 | 59.9 | 59.9 |
| Account Receivables, % | 0.03418626 | 26.52 | 0.03340339 | 0 | 53.88 | 16.09 | 16.09 | 16.09 | 16.09 | 16.09 |
| Inventories | .0 | .0 | .0 | -11.2 | .0 | -74.3 | -74.3 | -74.4 | -74.4 | -74.5 |
| Inventories, % | 0.000000345 | 0 | 0 | -2568.81 | 0 | -20 | -20 | -20 | -20 | -20 |
| Accounts Payable | 5.9 | 9.1 | 14.8 | 27.4 | 38.1 | 158.9 | 159.0 | 159.1 | 159.2 | 159.3 |
| Accounts Payable, % | 2.05 | 1674.77 | 1.62 | 6290.83 | 10.28 | 42.79 | 42.79 | 42.79 | 42.79 | 42.79 |
| Capital Expenditure | -6.7 | -18.4 | -81.7 | -37.2 | -12.0 | -159.3 | -159.4 | -159.5 | -159.6 | -159.7 |
| Capital Expenditure, % | -2.31 | -3380.85 | -8.95 | -8529.36 | -3.22 | -42.9 | -42.9 | -42.9 | -42.9 | -42.9 |
| Tax Rate, % | -1.92 | -1.92 | -1.92 | -1.92 | -1.92 | -1.92 | -1.92 | -1.92 | -1.92 | -1.92 |
| EBITAT | 46.4 | -355.3 | 371.7 | -672.8 | -226.8 | -150.4 | -150.4 | -150.5 | -150.6 | -150.7 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | 50.3 | -361.3 | 313.5 | -661.7 | -419.4 | 180.8 | -154.5 | -154.6 | -154.6 | -154.7 |
| WACC, % | 11.74 | 11.75 | 11.74 | 11.75 | 11.75 | 11.74 | 11.74 | 11.74 | 11.74 | 11.74 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -260.6 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -158 | |||||||||
| Terminal Value | -1,620 | |||||||||
| Present Terminal Value | -930 | |||||||||
| Enterprise Value | -1,190 | |||||||||
| Net Debt | -151 | |||||||||
| Equity Value | -1,039 | |||||||||
| Diluted Shares Outstanding, MM | 79 | |||||||||
| Equity Value Per Share | -13.12 |
What You Will Get
- Genuine CRISPR Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures for CRISPR Therapeutics AG (CRSP).
- Complete Customization: Modify all essential parameters (yellow cells) such as WACC, growth %, and tax rates to fit your analysis.
- Real-Time Valuation Updates: Automatic recalculations to evaluate the effects of changes on CRISPR Therapeutics AG (CRSP)'s fair value.
- Flexible Excel Template: Designed for quick adjustments, scenario analysis, and comprehensive projections.
- Efficient and Precise: Avoid starting from scratch while ensuring accuracy and adaptability in your financial modeling.
Key Features
- Comprehensive Data: CRISPR Therapeutics AG’s (CRSP) historical financial statements and pre-filled forecasts.
- Customizable Parameters: Adjust WACC, tax rates, revenue growth, and EBITDA margins as needed.
- Real-Time Insights: View CRISPR’s intrinsic value recalculated instantly.
- Intuitive Visuals: Dashboard charts present valuation results and essential metrics clearly.
- Designed for Precision: A robust tool tailored for analysts, investors, and finance professionals.
How It Works
- 1. Access the Template: Download and open the Excel file containing CRISPR Therapeutics AG’s preloaded data.
- 2. Modify Assumptions: Adjust key inputs such as growth projections, WACC, and capital expenditures.
- 3. View Results Instantly: The DCF model automatically calculates intrinsic value and NPV based on your inputs.
- 4. Explore Scenarios: Evaluate various forecasts to analyze different valuation possibilities.
- 5. Present with Assurance: Deliver professional valuation insights to back your investment decisions.
Why Choose CRISPR Therapeutics AG (CRSP)?
- Innovative Solutions: Pioneering gene-editing technologies to address unmet medical needs.
- Robust Pipeline: A diverse range of therapies in development for various genetic disorders.
- Expert Team: Led by industry leaders with extensive experience in biotechnology and genetics.
- Commitment to Research: Continuous investment in R&D to drive advancements in gene therapy.
- Strong Partnerships: Collaborations with top institutions and organizations to enhance innovation.
Who Should Use CRISPR Therapeutics AG (CRSP)?
- Investors: Gain insights into cutting-edge gene-editing technologies to inform your investment strategies.
- Biotech Analysts: Streamline your research with comprehensive data on CRISPR Therapeutics' pipeline and market potential.
- Consultants: Easily modify reports and presentations to highlight CRISPR Therapeutics' innovations for clients.
- Healthcare Enthusiasts: Explore the transformative impact of gene therapy through real-life case studies and applications.
- Educators and Students: Utilize it as a resource for understanding advanced biotechnological concepts in academic settings.
What the Template Contains
- Pre-Filled Data: Contains CRISPR Therapeutics AG's historical financials and projections.
- Discounted Cash Flow Model: Editable DCF valuation model with automated calculations.
- Weighted Average Cost of Capital (WACC): A dedicated sheet for calculating WACC based on user-defined inputs.
- Key Financial Ratios: Assess CRISPR's profitability, efficiency, and leverage metrics.
- Customizable Inputs: Easily adjust revenue growth, profit margins, and tax rates.
- Clear Dashboard: Visual representations and tables summarizing essential valuation outcomes.